Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Luckily for you, we at StockStory have no conflicts of interest - our sole job is to help you find genuinely promising companies. That said, here is one stock likely to meet or exceed Wall Street’s lofty expectations and two where analysts may be overlooking some important risks.
Two Stocks to Sell:
Advanced Drainage (WMS)
Consensus Price Target: $182.25 (36.8% implied return)
Originally started as a farm water drainage company, Advanced Drainage Systems (NYSE: WMS) provides clean water management solutions to communities across America.
Why Is WMS Not Exciting?
- Annual revenue growth of 5.2% over the last two years was below our standards for the industrials sector
- Earnings per share lagged its peers over the last two years as they only grew by 2.4% annually
- Eroding returns on capital suggest its historical profit centers are aging
Advanced Drainage’s stock price of $133.19 implies a valuation ratio of 20.2x forward P/E. If you’re considering WMS for your portfolio, see our FREE research report to learn more.
Integra LifeSciences (IART)
Consensus Price Target: $19.56 (21.3% implied return)
Founded in 1989 as a pioneer in regenerative medicine technology, Integra LifeSciences (NASDAQ: IART) develops and manufactures medical technologies for neurosurgery, wound care, and surgical reconstruction, including regenerative tissue products and surgical instruments.
Why Do We Avoid IART?
- Organic sales performance over the past two years indicates the company may need to make strategic adjustments or rely on M&A to catalyze faster growth
- Performance over the past five years shows its incremental sales were much less profitable, as its earnings per share fell by 4.6% annually
- 5× net-debt-to-EBITDA ratio makes lenders less willing to extend additional capital, potentially necessitating dilutive equity offerings
Integra LifeSciences is trading at $16.12 per share, or 6.2x forward P/E. To fully understand why you should be careful with IART, check out our full research report (it’s free).
One Stock to Buy:
Cencora (COR)
Consensus Price Target: $369.25 (20.7% implied return)
Formerly known as AmerisourceBergen until its 2023 rebranding, Cencora (NYSE: COR) is a global pharmaceutical distribution company that connects manufacturers with healthcare providers while offering logistics, data analytics, and consulting services.
Why Are We Bullish on COR?
- Unparalleled scale of $332.8 billion in revenue enables it to spread administrative costs across a larger membership base
- Share repurchases have amplified shareholder returns as its annual earnings per share growth of 14.4% exceeded its revenue gains over the last five years
- Industry-leading 50.2% return on capital demonstrates management’s skill in finding high-return investments
At $305.81 per share, Cencora trades at 16x forward P/E. Is now a good time to buy? See for yourself in our in-depth research report, it’s free.
Stocks We Like Even More
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
